A

AbbVie

Global biopharmaceutical company developing medicines

Account Specialist - Anti Infectives

Full-TimeUpdated on 10/23/2026
$78.5k - $192.5k/yr+ Short-term incentive program
Senior
Bachelor's
San Jose, CA, USA
RemoteCandidates should live within a reasonable distance from the primary city.
Sales & Account ManagementField Sales

About the job

Requirements
  • A bachelor's degree in health, sciences, pharmacy, or a business-related field is preferred, or relevant equivalent industry experience is required. In lieu of a bachelor's degree, at least five years of relevant industry experience is required; three or more years in the pharmaceutical, health, or science industry is preferred, and a high school diploma/GED is required.
  • Account-based selling experience in hospitals, wound care centers, or infusion centers, including experience building advocacy in hospitals for acute products, with or without a formulary win.
  • Experience navigating matrix environments within accounts and complex customers such as integrated delivery networks, academic institutions, hospitals, and outpatient accounts.
  • Knowledge of the formulary approval process and experience driving formulary approvals.
  • Documented strong sales performance as a consistent top performer in a challenging market or product portfolio.
  • Advanced sales skills, including communicating novel or complex products and processes simply, addressing customer concerns, advancing sales, and gaining new business.
  • Ability to work as an individual contributor in a collaborative environment.
  • Business acumen, individual accountability, ownership of a sales geography, multitasking, problem solving, and influencing without authority.
  • Ability to prioritize and manage multiple accounts effectively.
  • Analytical ability to analyze diverse datasets using multiple tools and define account and program strategies.
  • Strong planning and organizational skills, presentation and facilitation skills, and problem-resolution skills.
  • Ability to learn procedural, technical, and clinical information quickly and to understand, articulate, and routinely present complex scientific information to varied audiences.
  • Ability to cover the assigned geography and travel adequately to cover the territory, including overnight attendance at scheduled training events and sales meetings.
  • Valid driver's license, ability to pass a pre-employment drug screening test, and ability to meet safe-driving requirements.
  • Ability to drive a personal or company vehicle, or powered material-handling equipment.
  • Must satisfy applicable healthcare industry representative credentialing requirements to gain and maintain facility access, and be in good standing or eligible to obtain the credentials. Requirements may include background checks, drug screens, immunization or vaccination proof, fingerprinting, and licenses required by individual states or cities.
Responsibilities
  • Maximize opportunities for the product portfolio within the assigned geography by developing and maintaining strategic relationships with hospitals, integrated delivery networks, academic institutions, outpatient accounts, long-term care facilities, government accounts, and specialty private practices.
  • Increase patient access to portfolio products in accordance with approved labels, develop new business, expand current business, maximize resource utilization, and increase sales to achieve geography goals through a solution-oriented and collaborative approach.
  • Advance hospital and specialty customers along the sales continuum and gain prescriber commitments through effective questioning, active listening, and use of approved data and resources.
  • Deliver on-label presentations and sales calls that highlight product benefits and risks, create awareness of product solutions, address therapeutic-area gaps, and support sales goal achievement.
  • Differentiate the Anti-Infective portfolio's value proposition and develop professional relationships with executives, physicians, hospital staff, and support personnel to further product use within accounts and departments.
  • Understand and solve product and patient-flow issues across specialty pharmacy, specialty distribution, and buy-and-bill channels; coordinate stakeholders across departments with competing goals to align on patient-focused solutions.
  • Identify and address customer needs; build relationships that provide market intelligence and support compliant, innovative programs and initiatives that benefit patients, physicians, and other healthcare professionals.
  • Collaborate in a complex, matrixed, account-based selling environment with field and in-house cross-functional partners to identify, design, or adapt appropriate approaches and tactics.
  • Create, develop, execute, and monitor strategic geography business plans; determine appropriate department, channel, healthcare-professional focus, and account contact frequency; align resources and adjust tactics as needed.
  • Source, interpret, and use account data to maintain working account profiles and relationship maps; target key stakeholders and decision-makers to expand physician usage and the customer base.
  • Attend and participate in local boards, societies, conventions, and other healthcare-professional meetings as appropriate; represent the company and assigned products, build relationships, and share relevant information with internal partners. Communications in these forums must be on-label.
  • Complete required company training and comply with company policies and legal procedures.
  • Meet healthcare industry representative credentialing requirements for entry into facilities and organizations in the assigned territory.
  • Collaborate across healthcare institution departments and organizations; work with account directors and medical science liaisons to develop account processes and compliant communication strategies.
Desired Qualifications
  • Three or more years of experience within the pharmaceutical, health, or science industry.
  • Experience with buy-and-bill and specialty pharmacy products.

About the company

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
  • EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
  • JUVMO launches in October 2026, adding a fresh neuroscience revenue line.

What critics are saying

  • Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
  • Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
  • Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.

What makes AbbVie unique

  • Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
  • JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
  • AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Professional Development Budget

Growth & Insights and Company News

6 month growth

4%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Oct 24th, 2026
AbbVie wins FDA nod for at-home Skyrizi starts in Crohn's; sales boost seen after 60-90 days

AbbVie won US Food and Drug Administration (FDA) approval on October 23 for an at-home start to Skyrizi in adults with moderately to severely active Crohn's disease. Patients previously had to begin with intravenous infusions; they can now take the first doses at home with an on-body injector. By Week 12, 74% of patients new to advanced therapy reached clinical remission, against 27% on placebo. Johnson & Johnson's rival Tremfya won similar approval about 19 months earlier. Chief commercial officer Jeff Stewart said full paid access "will probably take 60 or 90 days" because insurers must approve the regimen. Sales impact should therefore come mostly after the fourth quarter. AbbVie reports third-quarter results on October 30. It guides for revenue of about $17.2 billion; Skyrizi's franchise sold $17.562 billion in 2025.

Yahoo Finance
Oct 23rd, 2026
ETFs net sell $42.1M of AbbVie as XLV leads $32.0M exit

Exchange-traded funds (ETFs) were net sellers of AbbVie shares for a second straight session, selling a net $42.1 million on October 21. Sellers moved larger sums even though more funds bought than sold: 24 ETFs added shares and 23 cut them. The Health Care Select Sector SPDR Fund led the selling with $32.0 million, followed by iShares Core S&P 500 ETF at $9.3 million and SPDR S&P 500 ETF Trust at $2.0 million. On October 20, ETFs sold a net $6.7 million, after three days of net buying. AbbVie has a market cap of $504.0 billion. Trailing 12-month revenue was $64.39 billion, up 10.3% over the past year.

Yahoo Finance
Oct 22nd, 2026
Abbott stock: $247,767 in shares yields $500 a month in dividends ahead of Q3 earnings

Abbott Laboratories will report third-quarter earnings before the market opens on Wednesday, October 21. Analysts expect earnings of $1.41 per share, up from $1.30 a year earlier, and revenue of $12.99 billion, against $11.37 billion last year. On October 16, TD Cowen analyst Joshua Jennings reiterated a Buy rating and a $135 price target. Abbott pays a quarterly dividend of 63 cents per share ($2.52 a year), a yield of 2.42%. To earn $500 a month ($6,000 a year) from dividends alone, an investor would need about 2,381 shares, or roughly $247,767.

Yahoo Finance
Oct 21st, 2026
Retirees swap Social Security for 5 dividend stocks yielding up to 6.64%

Retirees looking for income beyond Social Security are turning to dividend stocks. The 2027 cost-of-living adjustment is tracking toward 3.3%, and five companies from different industries were screened for dividend safety first, then yield. Verizon yields 6.64% and Altria 6.17%. Verizon's free cash flow guidance of $21.94 billion to $22.14 billion covers its roughly $11.76 billion annual dividend. Altria's payout is about 79% of the low end of its 2026 earnings guidance. Realty Income pays monthly at a 5.99% yield and has raised its dividend 115 consecutive quarters. Enbridge yields 5.95%. AbbVie yields 2.48%, but its quarterly dividend has grown from $0.40 in 2013 to $1.73 in 2026. Risks include satellite competition for Verizon, falling cigarette volumes for Altria, and currency swings for Enbridge.

Yahoo Finance
Oct 19th, 2026
Merck and AbbVie shares jump 39% and 24% in 2026 as dividend picks for a decade

Healthcare stocks are rebounding in 2026, led by Merck and AbbVie. Merck shares have climbed 39% and AbbVie's 24%, against about 12% for the S&P 500. Merck's second-quarter revenue rose 5% to $16.6 billion, beating Wall Street estimates. Keytruda sales hit $8.4 billion, though the drug will likely lose patent exclusivity by 2028. A subcutaneous version, Keytruda Qlex, may help retain market share. Merck's forward dividend yield is 2.3%. AbbVie's revenue grew 10.2% to almost $17 billion, with adjusted earnings per share up 22.9% to $3.65. Skyrizi and Rinvoq sales each rose about 24%, and neither faces US competition until 2033 and 2037 respectively. AbbVie has raised its dividend for 54 straight years, including its time as part of Abbott Laboratories.